Plasmid Borne Resistance in Klebsiella Isolates from Kenyatta National Hospital, Nairobi, Kenya

Eighty six Klebsiella isolates from Kenyatta National Hospital and the Centre for Microbiology, Kenya Medical Research Institute, Nairobi were screened forresistance to commonly prescribed antimicrobial agents and for their plasmidcontent. Plasmids were transferred into Esherichia coli K-12 and resultingtransconjugants screened for resistance to the antimicrobial agents used onKlebsiella donors and for their plasmid content. Plasmids from the Klebsiellaisolates were also transformed into Eschericia coli and transformants analyzedfor resistance and plasmid content. Endonuclease restriction mapping was done to characterize the plasmids from Klebsiella isolates and their Eschericia coli transformants. Resistance was found to be plasmid borne and transmissible

IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life

BACKGROUND: Data suggest that antibody responses to malaria parasites merozoite antigens are generally short-lived and this has implications for serological studies and malaria vaccine designs. However, precise data on the kinetics of these responses is lacking. METHODS: IgG1 and IgG3 responses to five recombinant Plasmodium falciparum merozoite antigens (MSP-119, MSP-2 type A and B, AMA-1 ectodomain and EBA-175 region II) among Kenyan children were monitored using ELISA for 12 weeks after an acute episode of malaria and their half-lives estimated using an exponential decay model. RESULTS: The responses peaked mainly at week 1 and then decayed rapidly to very low levels within 6 weeks. Estimation of the half-lives of 40 IgG1 responses yielded a mean half-life of 9.8 days (95% CI: 7.6-12.0) while for 16 IgG3 responses it was 6.1 days (95% CI: 3.7-8.4), periods that are shorter than those normally described for the catabolic half-life of these antibody subclasses. CONCLUSION: This study indicates antibodies against merozoite antigens have very short half-lives and this has to be taken into account when designing serological studies and vaccines based on the antigens